WP
GLUE icon

Woodline Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Woodline Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Buy
962,884
+888,388
+1,193% +$16.8M 0.07% 335
2026
Q1 		$1.23M Buy
+74,496
New +$1.42M ﹤0.01% 858
2023
Q1 		– Sell
-511,351
Closed -$3.89M – 697
2022
Q4 		$3.89M Buy
511,351
+8,940
+2% +$74.5K 0.05% 354
2022
Q3 		$4.11M Buy
502,411
+126,403
+34% +$1.16M 0.06% 336
2022
Q2 		$3.64M Buy
376,008
+327,908
+682% +$3.29M 0.06% 305
2022
Q1 		$674K Buy
48,100
+75
+0.2% +$1.04K 0.01% 503
2021
Q4 		$981K Sell
48,025
-86,008
-64% -$1.8M 0.01% 505
2021
Q3 		$2.99M Sell
134,033
-74,035
-36% -$2.12M 0.05% 340
2021
Q2 		$4.72M Buy
+208,068
New +$4.24M 0.09% 229

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners's GLUE Position: Q2 2026 in Review

Woodline Partners increased its Monte Rosa Therapeutics (GLUE) stake by 1,193% in Q2 2026, buying an estimated $16.8M and bringing the position to 962,884 shares worth $23.3M. The position accounts for 0.07% of the portfolio, ranked #335.

Woodline Partners first reported a position in GLUE in Q2 2021 and has held it in 9 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Woodline Partners held 962,884 shares of Monte Rosa Therapeutics worth $23.3M as of Q2 2026.
  • Woodline Partners bought 888,388 Monte Rosa Therapeutics shares in Q2 2026, an estimated $16.8M.
  • Monte Rosa Therapeutics made up 0.07% of Woodline Partners's portfolio in Q2 2026, its #335 holding.
  • Woodline Partners first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.